A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Public ClinicalTrials.gov record NCT05571839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.
Study identification
- NCT ID
- NCT05571839
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2, 2023
- Primary completion
- May 31, 2026
- Completion
- May 31, 2026
- Last update posted
- Jun 30, 2026
2023 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology - Administrative Office | Los Angeles | California | 90024 | — |
| The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate | Los Angeles | California | 90025 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Ronald Reagan UCLA Medical Center, Drug Information Center | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| UCLA Hematology/ Oncology- Pasadena | Pasadena | California | 91105 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| UCSF Medical Center, Investigational Pharmacy | San Francisco | California | 94158 | — |
| UCLA Hematology/Oncology - Santa Barbara | Santa Barbara | California | 93101 | — |
| The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only) | Santa Monica | California | 90404 | — |
| UCLA Hematology - Oncology Clinic - Westlake Village | Westlake Village | California | 91361 | — |
| Quest Diagnostics Incorporated - Denver | Denver | Colorado | 80209 | — |
| Presbyterian/St. Lukes Medical Center | Denver | Colorado | 80218 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| BWH | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute (DFCI) | Boston | Massachusetts | 02215 | — |
| Laboratory Corporation of America | Raritan | New Jersey | 08869 | — |
| Ambulatory Care Center at NYU Langone Medical Center | New York | New York | 10016 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| NYU Langone Hospitals, NYU Langone Rusk Ambulatory Surgical Pharmacy | New York | New York | 10016 | — |
| NYU Langone Medical Center(Tisch Hospital) | New York | New York | 10016 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Baylor Sammons Cancer Center | Dallas | Texas | 75251 | — |
| US Oncology Investigational Products Center (IPC) | Irving | Texas | 75063 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05571839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05571839 live on ClinicalTrials.gov.